Treatment adherence in psoriatic patients during COVID‐19 pandemic: Real‐world data from a tertiary hospital in Greece

Vakirlis, Efstratios; Bakirtzi, K; Papadimitriou, Ilias; Vrani, F.; Sideris, Nikolaos; Lallas, Aimilios; Ioannides, Dimitrios; Sotiriou, Elena

doi:10.1111/jdv.16759

Cited by 20 publications

(34 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9 Because issues such as hospital applies and treatment follow-up were interrupted, it has also been shown that the severity of psoriasis increases in patients during the pandemic period. 10 During this period, 29.1% of our patients applied for the previous chronic skin disease. It was found that about half of these patients reduced or stopped their treatment.…”

Section: Discussionmentioning

confidence: 95%

“…During the pandemic period, some concerns have arisen that chronic skin diseases will get worse 9 . Because issues such as hospital applies and treatment follow‐up were interrupted, it has also been shown that the severity of psoriasis increases in patients during the pandemic period 10 . During this period, 29.1% of our patients applied for the previous chronic skin disease.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Evaluation of the effect of COVID ‐19 pandemic on dermatological diseases with dermatological quality life index

Daye

Temiz

Işık

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Disease-related skin lesions have been reported in 8% to 20% of COVID-19 patients. In the literature, cutaneous symptoms associated with the disease are generally emphasized. However, there are very few studies on the effect of this new SARS-CoV-2 virus entering our lives on dermatological diseases, and none of them have used the dermatological quality of life index (DLQI). In our study, we aimed to evaluate the difficulties faced by the patients who applied to the dermatology outpatient clinic during the pandemic period and the course of their diseases with the dermatological quality of life index. The study was carried out prospectively by including dermatology patients who will apply to the outpatient clinic in June-July 2020. 282 patients were evaluated in the study. DLQI was significantly lower in the group using regular emollients (P < .001). When DLQI was compared between disease groups, it was found to be significantly different (P: .017). DLQI was found to worsen significantly compared to prepandemic studies. It was found that using moisturizer in this period helps to maintain the dermatological quality of life.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 97%

Evaluation of the effect of COVID ‐19 pandemic on dermatological diseases with dermatological quality life index

Daye

Temiz

Işık

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Comparing our results with those of other recently published studies, our rate of discontinued therapies is much lower. 5,6 Undoubtedly, in the total result, the smallest sample certainly had an influence.…”

mentioning

confidence: 96%

Adherence to biological therapy in dermatological patients during the COVID‐19 pandemic in Western Sicily

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In some areas, the suspension of all outpatient services was mandated, including clinics for psoriasis patients, and dermatologists had to adapt to provide more counseling to support patients, detect unmet needs, find ways to reassure patients about their disease, and keep them safe at home [ 77 ]. The adherence of patients with psoriasis that were treated with systemic therapies was analyzed in an observational single-institution study [ 78 ]. A total of 237 patients with psoriasis were interviewed by telephone.…”

Section: Biologics For Psoriasismentioning

confidence: 99%

Biologics for Psoriasis during the COVID-19 Pandemic

Komine

Ohtsuki

2021

JCM

View full text Add to dashboard Cite

Psoriasis is a chronic, immune-mediated inflammatory disease that predominantly affects the skin and joints. The recent therapeutic development for psoriasis has been remarkable and biologics have dramatically changed the treatment of psoriasis. In moderate-to-severe cases, systemic therapies are required to control their symptoms and biologics can provide greater efficacy when compared with other types of therapies. The coronavirus disease (COVID-19) pandemic has had a great impact on the lives of many people and has worsened substantially worldwide. During the ongoing COVID-19 pandemic, it still remains unclear whether biologics suppress the immune system and increase the risk of COVID-19. In this review, we have summarized the experience with biologics used for treating psoriasis during the COVID-19 pandemic. Biologics seem to be beneficial to COVID-19 infection. Shared decision-making that is based on updated information is highlighted in the time of COVID-19.

show abstract

Treatment adherence in psoriatic patients during COVID‐19 pandemic: Real‐world data from a tertiary hospital in Greece

Cited by 20 publications

References 8 publications

Evaluation of the effect of COVID ‐19 pandemic on dermatological diseases with dermatological quality life index

Evaluation of the effect of COVID ‐19 pandemic on dermatological diseases with dermatological quality life index

Adherence to biological therapy in dermatological patients during the COVID‐19 pandemic in Western Sicily

Biologics for Psoriasis during the COVID-19 Pandemic

Contact Info

Product

Resources

About